129 related articles for article (PubMed ID: 9466358)
21. Anomalies in reduction-mediated technetium-99m labelling of monoclonal antibodies.
Pimm MV; Rajput RS; Frier M; Gribben SJ
Eur J Nucl Med; 1991; 18(12):973-6. PubMed ID: 1778209
[TBL] [Abstract][Full Text] [Related]
22. [Labeling of CDTPA-dianhydride-coupled CD45 monoclonal antibody with yttrium-90].
Fu YB; Li GP; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1230-2. PubMed ID: 16939927
[TBL] [Abstract][Full Text] [Related]
23. Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.
Stalteri MA; Mather SJ
Eur J Nucl Med; 1996 Feb; 23(2):178-87. PubMed ID: 8925853
[TBL] [Abstract][Full Text] [Related]
24. A computer program for quantification of SH groups generated after reduction of monoclonal antibodies.
Iznaga Escobar N; Morales A; Núñez G
Nucl Med Biol; 1996 Jul; 23(5):635-9. PubMed ID: 8905829
[TBL] [Abstract][Full Text] [Related]
25. Reduction-mediated technetium-99m labeling of monoclonal antibodies.
Mather SJ; Ellison D
J Nucl Med; 1990 May; 31(5):692-7. PubMed ID: 2341907
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification.
Fernandez-Sánchez E; Ducongé J; Castillo R; Garcia I; Beausoleil I; Macías A
J Pharm Pharmacol; 2002 Jan; 54(1):59-64. PubMed ID: 11829130
[TBL] [Abstract][Full Text] [Related]
27. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
28. Technetium-99m labeled monoclonal antibodies: evaluation of reducing agents.
Thakur ML; DeFulvio J; Richard MD; Park CH
Int J Rad Appl Instrum B; 1991; 18(2):227-33. PubMed ID: 2026499
[TBL] [Abstract][Full Text] [Related]
29. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy.
Vrouenraets MB; Visser GW; Loup C; Meunier B; Stigter M; Oppelaar H; Stewart FA; Snow GB; van Dongen GA
Int J Cancer; 2000 Oct; 88(1):108-14. PubMed ID: 10962447
[TBL] [Abstract][Full Text] [Related]
30. Direct 99mTc-labeling of antibodies by sodium dithionite reduction, and role of ascorbate as a stabilizer in cysteine challenge.
Qi P; Muddukrishna SN; Torok-Both R; Rahn J; Chen A
Nucl Med Biol; 1996 Aug; 23(6):827-35. PubMed ID: 8940727
[TBL] [Abstract][Full Text] [Related]
31. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
[TBL] [Abstract][Full Text] [Related]
32. Technetium-99m-labeled monoclonal antibody with preserved immunoreactivity and high in vivo stability.
Arano Y; Yokoyama A; Furukawa T; Horiuchi K; Yahata T; Saji H; Sakahara H; Nakashima T; Koizumi M; Endo K
J Nucl Med; 1987 Jun; 28(6):1027-33. PubMed ID: 3585492
[TBL] [Abstract][Full Text] [Related]
33. Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m.
Childs RL; Hnatowich DJ
J Nucl Med; 1985 Mar; 26(3):293-9. PubMed ID: 3882905
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
[TBL] [Abstract][Full Text] [Related]
35. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
36. Interaction of a monoclonal antibody against hEGF with a receptor site for EGF.
Valente S; Souto B; Balter H; Welling MM; Román E; Robles A; Pauwels EK
Nucl Med Biol; 1999 Nov; 26(8):937-42. PubMed ID: 10708308
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
38. Biodistribution and preparation of technetium-99m-labeled D-D₃ monoclonal antibody against pro-gastrin-releasing peptide (₃₁₋₉₈) in mice.
Hao LJ; Hong ZH; Shi YZ; Liu ZL; Zhou XL
Chin Med J (Engl); 2013 Apr; 126(7):1333-6. PubMed ID: 23557567
[TBL] [Abstract][Full Text] [Related]
39. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.
Perera RM; Zoncu R; Johns TG; Pypaert M; Lee FT; Mellman I; Old LJ; Toomre DK; Scott AM
Neoplasia; 2007 Dec; 9(12):1099-110. PubMed ID: 18084617
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
